CHICAGO -- Novel orexin receptor 2 agonist oveporexton normalized wakefulness for most people with narcolepsy type 1 in two ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...

A new drug being trialed in heart attack patients could reprogram the immune system to prevent inflammation and heart damage ...

Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer ...

Bristol Myers Squibb have extended their research collaboration aimed at designing and optimizing small-molecule drugs for ...

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug ...

In 2023, the groundbreaking Australian BANDIT (Baricitinib in New Onset Type 1 Diabetes) trial [1] reported that a daily pill of baricitinib, commonly prescribed for rheumatoid arthritis and alopecia, ...

Eli Lilly (LLY) stock is in focus as the company's oral weight loss candidate orforglipron succeeds in two Phase 3 trials for ...

Scotland’s first national drug testing and research laboratory has been announced. The Scottish Government said the lab will ...

The U.S. Food and Drug Administration (FDA) has approved a new nonhormonal treatment to help women manage menopause symptoms ...

Researchers in Sweden are testing a 250-year-old medicine in patients with one of the world's deadliest cancers.